Seeking Alpha

Pharmacyclics (PCYC +1.4%) moves up after Roth Capital ups its price target on the shares to $42...

Pharmacyclics (PCYC +1.4%) moves up after Roth Capital ups its price target on the shares to $42 from $21. Roth thinks the market potential for the drug developer's lymphoma treatment ibrutinib is quite large, and it's impressed by the speed of the clinical program for the drug.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|